Bhatt Vijaya R, Giri Smith, Verma Vivek, Dahal Sumit, Shah Binay K, Pathak Ranjan, Bociek R Gregory, Vose Julie M, Armitage James O
Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, NE 68198, USA.
Department of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Future Oncol. 2016 Jul;12(13):1565-75. doi: 10.2217/fon-2016-0048. Epub 2016 Apr 15.
This large population-based study determined the epidemiology and outcomes of secondary acute myeloid leukemia (sAML) developing in Hodgkin lymphoma survivors.
We utilized the Surveillance Epidemiology and End Results (SEER) 9 database to identify 104 cases of sAML.
Patients with sAML (median age: 47 years; 82% <60 years) were significantly younger than de novo AML cases (66 years; p < 0.01). sAML had worse overall survival (OS) than de novo AML (p < 0.01). OS was better in younger patients and in more recent years.
Older patients with sAML have a dismal OS and should be enrolled in trials of novel therapies. Younger patients have improved OS and hence may benefit from curative intent intensive therapy and allogeneic transplant.
这项基于大规模人群的研究确定了霍奇金淋巴瘤幸存者中继发性急性髓系白血病（sAML）的流行病学情况及预后。
我们利用监测、流行病学和最终结果（SEER）9数据库识别出104例sAML病例。
sAML患者（中位年龄：47岁；82%＜60岁）显著比初发急性髓系白血病（AML）患者年轻（66岁；p＜0.01）。sAML的总生存期（OS）比初发AML更差（p＜0.01）。年轻患者以及近年来的患者OS更好。
老年sAML患者的OS较差，应纳入新型疗法试验。年轻患者的OS有所改善，因此可能从根治性强化治疗和异基因移植中获益。
